目的 探讨疏血通注射液联合注射用尼麦角林治疗急性脑梗死的临床疗效。方法 选取2017年1月—2018年6月南阳市中心医院收治的86例急性脑梗死患者为研究对象，全部患者随机分为对照组和治疗组，每组各43例。对照组静脉滴注注射用尼麦角林，4 mg加入到0.9%氯化钠注射液100 mL中，2次/d。治疗组在对照组的基础上静脉滴注疏血通注射液，6 mL加入到5%葡萄糖注射液250 mL中，1次/d。两组患者均持续治疗2周。观察两组的临床疗效，比较两组的神经损伤指标、细胞凋亡指标、脑血流参数、神经功能缺损评分。结果 治疗后，对照组和治疗组的总有效率分别为74.42%、90.70%，两组比较差异有统计学意义（P<0.05）。治疗后，两组的血清胰岛素样生长因子-1（IGF-1）、β-肌动蛋白（β-actin）和心型脂肪酸结合蛋白（H-FABP）水平较治疗前明显下降，比较差异有统计学意义（P<0.05）；且治疗组血清IGF-1、β-actin和H-FABP水平明显低于对照组，差异均有统计学意义（P<0.05）。治疗后，两组患者的血清半胱天冬酶-3（caspase-3）水平较同组治疗前下降，而血清B淋巴细胞瘤-2（Bcl-2）蛋白水平较同组治疗前上升，比较差异有统计学意义（P<0.05）；且治疗组各指标明显优于对照组优于对照组，差异均有统计学意义（P<0.05）。治疗后，两组的颈总动脉平均血流速度（V_mean）、颈动脉平均血流量（Q_mean）较同组治疗前均升高，脑血管外周阻力（R_v）较同组治疗前下降，比较差异有统计学意义（P<0.05）；且治疗组各指标明显优于对照组，差异均有统计学意义（P<0.05）。治疗后，两组患者美国国立卫生研究院卒中量表（NIHSS）评分较治疗前显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组NIHSS评分低于对照组，差异有统计学意义（P<0.05）。结论 疏血通注射液联合注射用尼麦角林治疗急性脑梗死具有较好的临床疗效，可降低神经功能损伤，抑制细胞凋亡，改善脑血流状态，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Shuxuetong Injection combined with Nicergoline for injection in treatment of acute cerebral infarction. Methods Patients (86 cases) with acute cerebral infarction in Nanyang Central Hospital from January 2017 to June 2018 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were iv administered with Nicergoline for injection, 4 mg added into normal saline 100 mL, twice daily. Patients in the treatment group were iv administered with Shuxuetong Injection on the basis of the control group, 6 mL added into 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and nerve injury indexes, apoptotic indexes, cerebral blood flow parameters, and neurological deficits in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.42% and 90.70%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of IGF-1, β-actin, and H-FABP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of caspase-3 in two groups were significantly decreased, but the levels of Bcl-2 in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, V_mean and Q_mean in two groups were significantly increased, but R_v in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, NIHSS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the NIHSS score in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Shuxuetong Injection combined with Nicergoline for injection has clinical effect in treatment of acute cerebral infarction, can reduce the damage of nerve function, inhibit apoptosis, and improve the state of cerebral blood flow, which has a certain clinical application value.